Lisinopril reduces mortality in patients with diabetes after acute MI

The GISSI-3 trial enrolled 18,131 patients of whom 2790 were diabetics. Treatment with lisinopril was associated with a significant 29.8 percent reduction in the six-week mortality among diabetics after myocardial infarction (MI), translating into 37 lives saved per 1000 patients. Lisinopril was less effective in nondiabetics; there was only a 5 percent reduction in mortality or three lives saved per 1000 patients.